Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends
The hypertension market is no stranger to new entrants, with therapies ranging from calcium channel blockers and angiotensin II receptor blockers (ARBs) to angiotensin-converting enzyme (ACE) inhibitors and beta blockers.…
When it comes to the degree of payer management within a therapeutic area, pharma companies are becoming the victim of their own successes. One prime example is the rapid growth…
In our collective experience working with dozens of clients, we’ve found that smaller pharma companies and biotechs wrestle with many common challenges, regardless of their therapeutic area. From limited budgets…
The category of treatments known as ‘digital therapeutics’ is widely misunderstood. Though the term is often conflated with ‘digital health’ tools, such as fitness trackers or meditation apps, digital therapeutics…
The CDC estimates that more than 33,000 Americans are living with hemophilia, an inherited bleeding disorder which affects primarily men. Patients with hemophilia have a deficiency of the blood proteins,…
This article was originally published in Pharmacy Times.
Amid a projected uptick in the prevalence of chronic diseases for an increasingly aging population, it’s more imperative than ever for patients…
This has been a significant year for the Humira (adalimumab) biosimilar market. AbbVie's blockbuster drug Humira, an injectable used to treat a range of inflammatory conditions, saw the end of…
This article was originally published in Drug Channels.
Over the past two decades, skyrocketing list prices for insulin have threatened medication adherence for the estimated 7.4 million American diabetics who rely…
For manufacturers, the success of a new brand hinges on its uptake in the first few months after launch. Many pharma companies are surprised to realize that payer coverage is…
Ever since the Inflation Reduction Act (IRA) became law, pharma companies have struggled to identify how these changes will affect their business. In many ways, the IRA is forcing a…
